Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet

Amass, Leslie; Kamien, Jonathan B.; Mikulich, Susan K.

doi:10.1016/s0376-8716(99)00074-5

Cited by 115 publications

(103 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, because buprenorphine has high affinity for opioid receptors (Hambrook and Rance 1976;Sadee et al 1982;Lewis et al 1983), moderately high BUP doses can block subjective and physiological effects of mu-opioids for more than 1 day (Jasinski et al 1978;Rosen et al 1994;Schuh et al 1999). Consistent with this human laboratory evidence, BUP has been shown to retain its efficacy using less-than-daily dosing schedules in several clinical trials (Fudala et al 1990;Amass et al 1994Amass et al , 1998Amass et al , 2000Johnson et al 1995b;Bickel et al 1999;Petry et al 1999).…”

Section: Introductionmentioning

confidence: 97%

Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans

et al. 2002

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 97%

Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Numerous clinical trials have evaluated the effectiveness of buprenorphine in comparison to placebo , clonidine (Ling et al, 2005;Gowling et al, 2004;Lintzeris et al, 2002), and methadone (Johnson et al, 1992;Johnson et al, 2000;Pani et al, 2000;Schottenfeld et al, 1997;Strain et al, 1994). Although buprenorphine may not be more effective than methadone, it has three key advantages: it does not require daily dosing (Amass et al, 2001), its chemical composition reduces the likelihood of diversion (Amass et al, 2000), and federal regulations encouraging its prescription by primary care physicians may facilitate its integration into community-based treatment programs (Amass et al, 2004). However, there are still are certain regulatory requirements that must be met in order for physicians to prescribe this medication (Koch et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters

Knudsen

Ducharme

Roman

2007

Drug and Alcohol Dependence

124

View full text Add to dashboard Cite

Despite growing interest in closing the "research to practice gap," there are few data on the availability of medications in American substance abuse treatment settings. Recent research suggests that organizational characteristics may be associated with medication availability. It is unclear if the availability of medications can be conceptualized in terms of "technology clusters," where the availability of a medication is positively associated with the likelihood that other medications are also offered. Using data from 403 privately funded and 363 publicly funded specialty substance abuse treatment centers in the US, this research models the availability of agonist medications, naltrexone, disulfiram, and SSRIs. Bivariate logistic regression models indicated considerable variation in adoption across publicly funded non-profit, government-owned, privately funded non-profit, and forprofit treatment centers. Some of these differences were attenuated by organizational characteristics, such as accreditation, the presence of staff physicians, and the availability of detoxification services. There was some evidence that naltrexone, disulfiram, and SSRIs represent a group of less intensely regulated medications that is distinct from more intensely regulated medications. These types of medications were associated with somewhat different correlates. Future research should continue to investigate the similarities and differences in the predictors of medication availability across national contexts.

show abstract

“…Buprenorphine is licensed in many countries for the treatment of moderate-to-severe pain. It is long-acting and, consequently, can be administered every 1, 2, or 3 days [17,18] . Buprenorphine has a relatively good safety profile and, compared to methadone, rarely results in clinically significant respiratory depression in cases of overdose.…”

Section: Introductionmentioning

confidence: 99%

Suboxone® (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis

Martı́nez-Raga

Saiz²,

Pascual³

et al. 2009

Eur Addict Res

View full text Add to dashboard Cite

Objective: To evaluate the economic impact of buprenorphine/naloxone (B/N) as an agonist opioid treatment for opiate dependence. Methods: A budgetary impact analysis model was designed to calculate the annual costs (drugs and associated costs) to the Spanish National Healthcare System of methadone versus B/N. Data for the model were obtained from official databases and expert panel opinion. Results: It was estimated that 86,017 patients would be in an agonist opioid treatment program each of the 3 years of the study. No increase in the number of patients is expected with the introduction of B/N combination. The budgetary impact (drugs and associated costs) for agonist opiate treatment in the first year of the study would be 89.53 million EUR. In the first year of B/N use, the budgetary impact would rise by 4.39 million EUR (4.6% of the total impact), with an incremental cost of 0.79 million EUR (0.9% of the total impact). The budgetary increase would be 0.6% (0.48 million EUR increase) and 0.6% (0.49 million EUR increase) in the second and third years of use, respectively. The mean cost per patient in the first year with and without B/N would be EUR 1,050 and 1,041, respectively. The most influential variables in the sensitivity analysis were logistics and production costs of methadone and the percentage use of B/N. Conclusion: With an additional cost of only EUR 9 per patient, B/N is an efficient addition to the therapeutic arsenal in the drug treatment of opiate dependence, particularly when considering clinical aspects of novel pharmacotherapy.

show abstract

Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet

Cited by 115 publications

References 25 publications

Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans

Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans

The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters

Suboxone® (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis

Contact Info

Product

Resources

About